Efficacy of lithium as acute treatment of manic-depressive illness.
Efficacy of lithium as acute treatment of manic-depressive illness.
复制标题
锂作为躁狂抑郁症急性治疗的功效。
DOI：
10.1016/s0140-6736(71)91886-1
复制
发表时间：
1971
期刊：
影响因子：
168.9
通讯作者：
MichaelJ. Patton
中科院分区：
文献类型：
--
作者：
P. Stokes;C. Shamoian;P. Stoll;MichaelJ. Patton
在38例躁狂抑郁症住院患者中，对锂和安慰剂交替使用7-10天的双盲比较表明，锂在躁狂症治疗中比安慰剂具有显著优势。在56个锂周期（0.5 meq.每公斤28名患者的平均剂量（每天）显著降低，但28名患者在42个安慰剂治疗期后没有显著降低。在锂盐治疗期间，75%的患者躁狂症减少，只有7%的患者躁狂症恶化;安慰剂治疗期间，40.5%的患者躁狂症减少，40.5%的患者躁狂症增加。在治疗的第7-10天，服用锂剂后的躁狂评分中位数显著低于服用安慰剂后，尽管服用锂剂前的躁狂评分往往较高。仅在最初的治疗期间，接受锂的患者在治疗后的评分就显着低于接受安慰剂的患者。“非典型”躁狂抑郁症（躁狂）患者的反应以及明显的典型病例。在锂治疗的第7-10天，血液锂水平与躁狂评分的降低之间没有显著相关性（平均0.93 meq。每升）和使用的相对较低剂量。在26个治疗阶段中，18名患者在行为抑郁期间开始，锂的59%改善率并不显著高于安慰剂的48%。
A double-blind comparison of alternating 7-10 day periods of lithium and placebo in thirty-eight manic-depressive inpatients demonstrated a significant advantage of lithium over placebo in mania. Median mania ratings after 56 periods of lithium (0.5 meq. per kg. per day) in twenty-eight patients decreased significantly, but did not decrease significantly after 42 periods of placebo in twenty-eight patients. Mania decreased in 75% of lithium periods and worsened in only 7%; mania decreased in 40.5% of placebo periods and increased in 40.5%. Median mania ratings during days 7-10 of treatment were significantly lower after lithium than after placebo, even though mania ratings immediately preceding lithium tended to be higher. In the initial treatment periods alone, patients receiving lithium had significantly lower ratings after treatment than patients receiving placebo. " Atypical " manic-depressive (manic) patients responded as well as did apparently typical cases. There was no significant correlation between lithium blood-levels and a decrement in mania ratings during days 7-10 of lithium treatment with the blood-levels attained (mean 0.93 meq. per litre) and the relatively low dose used. In 26 treatment periods in eighteen patients begun during behavioural depression, the 59% improvement-rate with lithium was not significantly higher than the 48% rate with placebo.